Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis
December 2, 2021
End-of-phase-2 response from the US regulatory agency (FDA) provides guidance and a path forward to advance ABX464 into a phase 3 clinical program in ulcerative colitis (UC)
